Literature DB >> 8490497

Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.

I Jacobs1, A P Davies, J Bridges, I Stabile, T Fay, A Lower, J G Grudzinskas, D Oram.   

Abstract

OBJECTIVE: To assess the performance of the sequential combination of serum CA 125 measurement and ultrasonography in screening for ovarian cancer.
DESIGN: The serum CA 125 concentration of each subject was determined and those with a concentration > or = 30 U/ml were recalled for abdominal ultrasonography. If ultrasonography gave abnormal results surgical investigation was arranged. Volunteers were followed up by annual postal questionnaire.
SETTING: General practice, occupational health departments, ovarian cancer screening clinic.
SUBJECTS: 22,000 women volunteers who were postmenopausal and aged over 45 years. MAIN OUTCOME MEASURES: Apparent sensitivity, specificity, positive predictive value, years of cancer detected.
RESULTS: 41 women had a positive screening result and were investigated surgically. 11 had ovarian cancer (true positive result) and 30 had other disorders or no abnormality (false positive result). Of the 21,959 volunteers with a negative screening result, eight subsequently presented clinically with ovarian cancer (false negative result) and 21,951 had not developed ovarian cancer during follow up (apparent true negative result). The screening protocol achieved a specificity of 99.9%, a positive predictive value of 26.8%, and an apparent sensitivity of 78.6% and 57.9% at one year and two year follow up respectively. The estimated number of years of cancer detected by the prevalence screen was 1.4 years.
CONCLUSIONS: This screening protocol is highly specific for ovarian cancer and can detect a substantial proportion of cases at a preclinical stage. Further investigation is required to determine the effect of the screening protocol on the ratio of early to late stage disease detected and on mortality from ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490497      PMCID: PMC1677033          DOI: 10.1136/bmj.306.6884.1030

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  18 in total

1.  Familial breast-ovarian cancer locus on chromosome 17q12-q23.

Authors:  S A Narod; J Feunteun; H T Lynch; P Watson; T Conway; J Lynch; G M Lenoir
Journal:  Lancet       Date:  1991-07-13       Impact factor: 79.321

2.  Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.

Authors:  N Einhorn; K Sjövall; R C Knapp; P Hall; R E Scully; R C Bast; V R Zurawski
Journal:  Obstet Gynecol       Date:  1992-07       Impact factor: 7.661

3.  Real-time ultrasonography for determination of ovarian morphology and volume. A possible early screening test for ovarian cancer?

Authors:  S Campbell; L Goessens; R Goswamy; M Whitehead
Journal:  Lancet       Date:  1982-02-20       Impact factor: 79.321

4.  Circulating tumor markers in the monitoring of gynecologic malignancies.

Authors:  P E Schwartz; S K Chambers; J T Chambers; J Gutmann; N Katopodis; R Foemmel
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

5.  Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer.

Authors:  V R Zurawski; H Orjaseter; A Andersen; E Jellum
Journal:  Int J Cancer       Date:  1988-11-15       Impact factor: 7.396

6.  Ovarian cancer: incidence and case-control study.

Authors:  J F Annegers; H Strom; D G Decker; M B Dockerty; W M O'Fallon
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

7.  Coordinate elevation of serum markers in ovarian cancer but not in benign disease.

Authors:  R C Bast; S Knauf; A Epenetos; B Dhokia; L Daly; M Tanner; J Soper; W Creasman; S Gall; R C Knapp
Journal:  Cancer       Date:  1991-10-15       Impact factor: 6.860

8.  Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.

Authors:  I J Jacobs; D H Oram; R C Bast
Journal:  Obstet Gynecol       Date:  1992-09       Impact factor: 7.661

9.  An epidemiologic study of epithelial carcinoma of the ovary.

Authors:  N G Hildreth; J L Kelsey; V A LiVolsi; D B Fischer; T R Holford; E D Mostow; P E Schwartz; C White
Journal:  Am J Epidemiol       Date:  1981-09       Impact factor: 4.897

10.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more
  53 in total

1.  Screening for ovarian cancer. We now need a definitive randomised trial.

Authors:  N Urban
Journal:  BMJ       Date:  1999-11-20

Review 2.  Forth nightly review: hereditary ovarian carcinoma.

Authors:  L Kasprzak; W D Foulkes; A N Shelling
Journal:  BMJ       Date:  1999-03-20

3.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

4.  Screening for ovarian cancer: recommendation statement.

Authors: 
Journal:  Ann Fam Med       Date:  2004 May-Jun       Impact factor: 5.166

5.  Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.

Authors:  Stefanos Bonovas; Kalitsa Filioussi; Nikolaos M Sitaras
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

6.  Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider.

Authors:  Haim A Abenhaim; Linda Titus-Ernstoff; Daniel W Cramer
Journal:  CMAJ       Date:  2007-03-27       Impact factor: 8.262

7.  Lights and shadows of the tumoral marker CA-125 in ovarian cancer.

Authors:  A Sánchez Muñoz; A González Martín; C Mendiola Fernández
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

8.  Ascertainment of familial ovarian cancer in the Aberdeen Genetic Clinic.

Authors:  H Gregory; A Schofield; D de Silva; J Semper; B Milner; L Allan; N Haites
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

9.  Giant serous papillary cystadenoma.

Authors:  Madhusudan Dey; Niloy Pathak
Journal:  Med J Armed Forces India       Date:  2011-08-07

10.  Phase II biomarker trial of a multimarker diagnostic for ovarian cancer.

Authors:  Tracey Edgell; G Martin-Roussety; G Barker; D J Autelitano; D Allen; P Grant; G E Rice
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.